Inactive Instrument

Metacrine, Inc. Stock

MTCR

US59101E1038

Biotechnology & Medical Research

Latest news about Metacrine, Inc.

Metacrine, Inc. Announces Board Changes	23-03-23	CI
Metacrine, Inc. Announces CEO Changes	23-03-23	CI
Metacrine, Inc.(OTCPK:MTCR) dropped from S&P TMI Index	23-02-13	CI
Metacrine, Inc.(OTCPK:MTCR) dropped from NASDAQ Composite Index	23-02-08	CI
Metacrine, Inc. Appoints Michael York as President	23-02-03	CI
Metacrine, Inc. Appoints Michael York as Chief Executive Officer	23-02-03	CI
Insider Sell: Metacrine	23-01-27	MT
North American Morning Briefing : China Optimism Gives Boost to Futures	22-12-27	DJ
Equillium, Metacrine Agree to Terminate Proposed Merger	22-12-27	MT
Metacrine, Equillium Mutually Agree to Terminate Merger Accord	22-12-23	MT
Equillium, Inc. (NasdaqGM:EQ) cancelled the acquisition of Metacrine, Inc. from a group of shareholders.	22-12-22	CI
Insider Buy: Metacrine	22-12-21	MT
Metacrine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Insider Buy: Metacrine	22-10-31	MT
Metacrine, Inc. Enters into A License Agreement with FL2022-001, Inc	22-10-11	CI

More news

Analyst Recommendations on Metacrine, Inc.

Jefferies Analyst Starts Metacrine at Hold, Adjusts Price Target to $1 From $2	21-12-29	MT
METACRINE : Canaccord Genuity Downgrades Metacrine to Hold Rating From Buy, Adjusts Price Target to $1 From $19	21-10-22	MT
METACRINE : Jefferies Downgrades Metacrine to Hold from Buy, Adjusts Price Target to $2 from $14	21-10-22	MT
METACRINE : HC Wainwright Downgrades Metacrine to Neutral from Buy	21-10-22	MT
METACRINE : RBC Downgrades Metacrine to Sector Perform From Outperform, Price Target to $2.50 From $22, Amid 'Mixed' NASH Data; Speculative Risk Kept	21-10-22	MT

More recommendations

Press releases Metacrine, Inc.

METACRINE, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	23-03-03	AQ
Metacrine : Termination of Material Agreement - Form 8-K	23-02-09	PU
METACRINE, INC. : Termination of a Material Definitive Agreement, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement (form 8-K)	23-02-09	AQ
METACRINE, INC. : Change in Directors or Principal Officers (form 8-K)	23-02-03	AQ
METACRINE, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	23-02-01	AQ

More press releases

Managers and Directors - Metacrine, Inc.

Managers	Title	Age	Since
Dave Maggio CEO	Chief Executive Officer	64	23-03-23

Members of the board	Title	Age	Since
H. Hogan BRD	Director/Board Member	61	23-03-22

More insiders

Metacrine, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal (GI) diseases. The Companyâs advanced program targets the farnesoid X receptor (FXR), which is central to modulating GI and liver diseases. The Companyâs pipeline includes MET642 and hydroxysteroid dehydrogenase 17B13 (HSD17B13 or HSD). MET642 is used for the treatment of inflammatory bowel disease (IBD) including ulcerative colitis (UC) and Crohnâs disease. HSD17B13 is used for the treatment of non-alcoholic steatohepatitis (NASH) and other liver diseases. The Company is pursuing the development of MET642 for the treatment of Ulcerative Colitis (UC). The Company has built a proprietary library of approximately 2,500 FXR compounds.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	-1.82%	41.36B
LONZA GROUP AG	+44.25%	41.3B
MODERNA, INC.	+2.56%	39.61B
CELLTRION, INC.	-12.11%	25.62B
ICON PUBLIC LIMITED COMPANY	+3.09%	24.09B
ALNYLAM PHARMACEUTICALS, INC.	-24.16%	18.38B
MEDPACE HOLDINGS, INC.	+22.12%	11.85B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.74%	11.82B
UNITED THERAPEUTICS CORPORATION	+7.75%	11.07B